Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0484 EUR | 0.00% | -11.36% | +40.70% |
17/06 | Percheron Therapeutics Appoints CFO | MT |
03/06 | Percheron Therapeutics Names Chief Medical Advisor | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+40.70% | 50.27M | - | ||
+16.49% | 122B | B+ | ||
+21.73% | 116B | B+ | ||
+22.18% | 27.03B | B | ||
-21.81% | 20.36B | B+ | ||
-16.89% | 16.43B | A- | ||
-18.81% | 15.91B | B | ||
-44.74% | 15.6B | A- | ||
+62.72% | 14.94B | C+ | ||
+3.09% | 13.59B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PER Stock
- AWY0 Stock
- Ratings Percheron Therapeutics Limited